SeaStar Medical (NASDAQ:ICU) versus Motus GI (NASDAQ:MOTS) Critical Comparison

SeaStar Medical (NASDAQ:ICUGet Free Report) and Motus GI (NASDAQ:MOTSGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Risk and Volatility

SeaStar Medical has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

11.6% of SeaStar Medical shares are held by institutional investors. Comparatively, 8.6% of Motus GI shares are held by institutional investors. 4.5% of SeaStar Medical shares are held by company insiders. Comparatively, 1.6% of Motus GI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares SeaStar Medical and Motus GI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SeaStar Medical N/A N/A -961.93%
Motus GI -3,776.10% -3,413.36% -96.95%

Valuation and Earnings

This table compares SeaStar Medical and Motus GI’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SeaStar Medical N/A N/A -$23.01 million N/A N/A
Motus GI $364,000.00 1.23 -$18.60 million ($35.91) -0.02

Motus GI has higher revenue and earnings than SeaStar Medical.

Analyst Ratings

This is a breakdown of current recommendations and price targets for SeaStar Medical and Motus GI, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SeaStar Medical 0 0 1 0 3.00
Motus GI 0 0 1 0 3.00

SeaStar Medical presently has a consensus target price of $5.00, indicating a potential upside of 395.05%. Motus GI has a consensus target price of $28.88, indicating a potential upside of 4,350.52%. Given Motus GI’s higher possible upside, analysts plainly believe Motus GI is more favorable than SeaStar Medical.

Summary

Motus GI beats SeaStar Medical on 5 of the 9 factors compared between the two stocks.

About SeaStar Medical

(Get Free Report)

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.

About Motus GI

(Get Free Report)

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.

Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.